{
  "id": 2362695,
  "title": "Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating",
  "url": "https://urgent.news/2026/08/21/cantor-fitzgerald-initiates-nuvation-bio-stock-with-overweight-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-21T10:52:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/cantor-fitzgerald-initiates-nuvation-bio-stock-with-overweight-rating-93CH-4871354"
  },
  "original_language": "en",
  "account": "Cantor Fitzgerald has begun tracking Nuvation Bio Inc (NYSE:NUVB) with an overweight rating and an ambitious 12-month price target of $12 per share. The firm's research focuses on two targeted therapies developed by the commercial-stage oncology company: Ibtrozi, a ROS1 inhibitor for ROS1-positive non-small cell lung cancer, and safusidenib, an IDH1 inhibitor in Phase 3 development for IDH1-mutant glioma. Cantor Fitzgerald anticipates peak sales of $965 million for Ibtrozi and approximately $1.9 billion for safusidenib. This pricing implies a 73% upside from the stock's current level of $6.83, which has surged 149% over the past year. Nuvation Bio boasts a market capitalization of about $2.6 billion and a strong gross profit margin of 88%. However, the company reported a loss per share of 18 cents in its second-quarter 2026 revenue of $31.7 million, exceeding Wall Street's estimate. Despite this, JPMorgan has also initiated coverage of Nuvation Bio with an overweight rating and a higher price target of $13.00, citing early success of its lead product in treating advanced ROS1+ non-small cell lung cancer.",
  "summary": null,
  "key_points": [
    "Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating",
    "Targets $12 per share price, 73% upside from current $6.83",
    "Focus on Ibtrozi and safusidenib therapies in oncology pipeline"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}